文献速递烧伤创面修复

重症监护感染评分在烧伤患者感染鉴别中的验证:ICARUS研究

Validation of the intensive care infection score for infection discrimination in burn patients compared with other inflammatory biomarkers (ICARUS study).
PubMed 文献 · Burns · 2026-03-17

ICIS鉴别感染的ROC曲线下面积为0.81(95%CI 0.69-0.92),优于多种常规标志物,支持其作为烧伤ICU感染评估的辅助生物标志物。

要点

  • ICIS鉴别烧伤ICU患者感染与非感染性炎症的AUC为0.81(95%CI 0.69-0.92)。
  • 患者层面分析显示ICIS对感染与非感染患者的区分度优于其他评估标志物。
  • ICIS为流式细胞术复合标志物,可作为烧伤ICU感染评估的辅助工具。

核心结论

  • 在危重烧伤患者中,患者层面分析时ICIS对感染性与非感染性炎症状态的鉴别优于多种常用生物标志物。
  • 研究结果支持ICIS作为烧伤ICU患者感染评估的辅助生物标志物,但尚需多中心研究验证其临床效用。

研究设计与样本

  • 前瞻性单中心观察性研究,纳入2021年6月至2022年8月成人烧伤ICU患者。
  • 感染状态采用复合临床参考标准回顾性判定,纳入微生物学结果、可获得的影像学及记录的抗菌治疗决策。

主要发现

  • 感染患者的ICIS值显著高于非感染患者。
  • ICIS鉴别感染的ROC曲线下面积为0.81(95%CI 0.69-0.92),优于多种常规生物标志物。
  • 患者层面比较中,ICIS在感染与非感染患者间的分离度大于其他评估标志物。

关键数值与推荐

  • ICIS鉴别感染的AUC为0.81(95%CI 0.69-0.92)。
  • 对比标志物包括CRP、PCT、WBC、LBP、presepsin和calprotectin。

临床怎么用

  • 在烧伤ICU中可将ICIS作为感染评估的辅助生物标志物,与常规标志物联合参考。
  • ICIS可能有助于抗菌药物管理,但其临床效用尚待多中心研究定义。

局限性

  • 感染状态为回顾性判定,采用反映常规烧伤ICU实践的复合临床参考标准。
  • 作者指出需进一步多中心研究验证结果并明确ICIS的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Distinguishing infection from non-infectious systemic inflammation remains a major challenge in critically ill burn patients. Conventional inflammatory biomarkers are frequently elevated following thermal injury, which may limit their diagnostic specificity. The Intensive Care Infection Score (ICIS) is a flow-cytometry-based composite biomarker that has not been systematically evaluated in burn patients. METHODS: In this prospective single-center observational study, adult burn ICU patients were included between June 2021 and August 2022. Infection status was determined retrospectively for each blood sample using a composite clinical reference standard incorporating microbiological findings, imaging when available, and documented antimicrobial treatment decisions, reflecting routine burn ICU practice. To avoid bias from repeated sampling, the primary analysis was performed at the patient level using one representative blood sample per patient. ICIS was compared with C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), lipopolysaccharide-binding protein (LBP), presepsin, and calprotectin. Discriminatory performance was assessed using receiver operating characteristic (ROC) analysis. RESULTS: Sixty patients were included in the study. Infected patients demonstrated significantly higher ICIS values compared with non-infected patients. ICIS showed the highest discriminatory performance for infection, with an area under the ROC curve of 0.81 (95% CI 0.69-0.92), outperforming several conventional biomarkers. Patient-level comparisons confirmed greater separation between infected and non-infected patients for ICIS than for other evaluated biomarkers. CONCLUSIONS: In critically ill burn patients, ICIS demonstrated superior discrimination between infectious and non-infectious inflammatory states compared with several commonly used biomarkers when analyzed at the patient level. These findings support the potential role of ICIS as an adjunctive biomarker for infection evaluation in burn ICU patients. Further multicenter studies are warranted to validate these results and to define the clinical utility of ICIS, including its potential contribution to antimicrobial stewardship.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Bakalář B, Zajíček R, Kubicová B, et al. Validation of the intensive care infection score for infection discrimination in burn patients compared with other inflammatory biomarkers (ICARUS study). Burns. 2026. PMID: 42119490. doi:10.1016/j.burns.2026.107975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。